NextBigThingInvestor.com Releases Two-Part Interview With Tobin Smith and Galmed Pharmaceuticals
‘Next Big Thing Report’ Highlights Estimated 45 Million Addressable Market for Galmed’s (“GLMD”) Aramchol™ Treatment of NASH Liver Disease
September 28, 2015